AUS
NZ
UK
CA
USA
IND
On July 28, 2026, Synchrony Financial filed a preliminary prospectus supplement announcing the issuance of fixed-to-floating rate senior notes in two separate series. This marks the company’s latest debt issuance under its current registration statement. The notes will initially carry fixed interest rates before converting to floating rates tied to Compounded SOFR plus a specified basis point spread after the fixed-rate period ends.
Key Points
- NYSE: SYF-PB
- Synchrony Financial submitted a preliminary prospectus supplement for two series of fixed-to-floating rate senior notes on July 28, 2026
- The offering features two distinct note series with different maturities; principal amounts, coupon rates, and maturity years remain undisclosed in the preliminary filing
- J.P. Morgan, TD Securities, and Wells Fargo Securities act as joint book-running managers for the issuance
Details on the Two-Series Fixed-to-Floating Senior Notes Offering
Synchrony Financial revealed plans to issue two separate series of fixed-to-floating rate senior notes through a preliminary prospectus supplement dated July 28, 2026. Both series will start with fixed interest rates payable semi-annually in arrears. Specific details on principal amounts, fixed coupon rates, and maturity dates were not included, as the preliminary prospectus supplement contains placeholders pending finalization.
Following the initial fixed-rate period, which will end on a date to be specified in the final prospectus, the notes will convert to floating-rate instruments. Interest during the floating-rate period will be calculated based on Compounded SOFR plus a predetermined basis point spread, with quarterly payments in arrears. This hybrid debt structure enables Synchrony to balance fixed-rate financing with exposure to floating rates aligned with market conditions.
Floating Rate Conversion and Interest Payment Terms
The prospectus supplement outlines the mechanism for transitioning to floating rates after the fixed-rate term concludes. Post-conversion, interest will be paid quarterly and calculated as Compounded SOFR plus an undisclosed basis point spread, which remains subject to completion in the final prospectus. Payment dates for the floating-rate period are referenced but not finalized.
During the fixed-rate phase, interest payments will be semi-annual, shifting to quarterly payments once the floating-rate period begins. Interest will accrue until each series’ maturity date. Pricing, underwriting discounts, and net proceeds to Synchrony are also pending final disclosure. Any accrued interest from July 2026 will be added to the purchase price, consistent with market conventions for debt offerings.
Senior Unsecured Debt Status and Redemption Rights
The notes will be senior unsecured obligations of Synchrony Financial, ranking pari passu with all other unsecured and unsubordinated debt the company has outstanding. This means noteholders share equal payment rights but are subordinate to secured creditors. The notes are not bank deposits or obligations of any Synchrony subsidiaries, nor are they insured or guaranteed by the FDIC or any government agency.
Synchrony retains the option to redeem notes of each series under terms to be finalized in the "Optional Redemption" section. This feature provides flexibility to refinance or repay debt early depending on market or business conditions. Investors should consult the final prospectus for detailed redemption provisions.
Underwriting Syndicate and Distribution Details
The underwriting syndicate is led by J.P. Morgan, TD Securities, and Wells Fargo Securities as joint book-running managers. These firms will coordinate sales of both note series to institutional and eligible investors. Additional underwriters may be named in the final prospectus.
Notes will be issued in book-entry form through The Depository Trust Company (DTC) for the benefit of DTC participants, including Clearstream Banking S.A. and Euroclear Bank SA/NV. The expected delivery date is on or about July 2026, subject to finalization. This settlement method ensures efficient custody and clearance within global securities infrastructure. The notes will not be listed or quoted on any exchange or automated system.
Registration and Regulatory Filings
The preliminary prospectus supplement filed July 28, 2026, is part of Synchrony Financial’s Registration Statement on Form S-3 (Registration No. 333-288729). The underlying prospectus is dated July 17, 2025, providing foundational disclosures for the company’s securities offerings. The filing complies with Rule 424(b)(5) of the Securities Act, allowing preliminary supplements before final terms are set.
The supplement incorporates by reference Synchrony’s other periodic filings, including its Annual Report on Form 10-K for the year ended December 31, 2025. Investors are advised to review all information in the supplement, accompanying prospectus, and any related free writing prospectuses. As a preliminary filing, specific terms and pricing remain subject to change before the final prospectus is issued.
Forward-Looking Statements and Investment Risks
Synchrony cautions that the prospectus supplement contains forward-looking statements about future business developments and financial performance, which involve risks and uncertainties that could cause actual results to differ materially. Investors should review the "Risk Factors" section starting on page S-11 of the supplement for detailed risk disclosures.
The filing notes that neither the SEC nor any regulatory authority has approved or disapproved the securities or verified the adequacy of the prospectus supplement. Any contrary representation is a criminal offense. The preliminary prospectus supplement is incomplete and subject to change prior to final publication.
Absence of Secondary Market and Liquidity Considerations
The notes will not be listed on any securities exchange or quoted on automated quotation systems, and no established secondary market currently exists. Investors should anticipate limited liquidity and that any resale prior to maturity would require negotiated transactions with other investors.
As the preliminary prospectus supplement is subject to completion, final offering terms, pricing, and market conditions may change before the notes are issued.
About Synchrony Financial and Its Operations
Synchrony Financial offers a broad range of credit products through programs with national and regional retailers, local merchants, manufacturers, buying groups, industry associations, and healthcare providers, collectively referred to as "partners." Its product suite includes the CareCredit brand for healthcare financing and consumer credit products via retail and commercial partnerships. Synchrony Bank, a subsidiary, serves as the bank affiliate for certain credit offerings.
The prospectus supplement incorporates Synchrony’s Annual Report on Form 10-K for the year ended December 31, 2025, which details the company’s financial condition, operational results, and strategic outlook. Investors seeking comprehensive information on Synchrony’s competitive position, regulatory environment, asset quality, and capital management should consult the full annual report and SEC filings available on EDGAR.
